Doramapimod is primarily used in research and clinical settings as a selective inhibitor of p38 MAP kinase, a protein involved in cellular responses to stress and inflammation. Its application is significant in studying inflammatory diseases, as it helps to understand the role of p38 MAP kinase in conditions like rheumatoid arthritis, Crohn's disease, and other autoimmune disorders. In preclinical studies, Doramapimod has shown potential in reducing inflammation and slowing disease progression, making it a valuable tool for developing targeted therapies. Additionally, it is explored in cancer research to investigate its effects on tumor growth and metastasis, particularly in cancers where p38 MAP kinase signaling is dysregulated. Its ability to modulate cellular pathways also makes it useful in studying mechanisms of cell survival and apoptosis.